Renée Hovenier

Ms. Renée Hovenier

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EGErika Galietta
Erika Galietta
CDCostanza Maria Donati
Costanza Maria Donati
Alberto BazzocchiAlberto Bazzocchi
Alberto Bazzocchi
RSRebecca Sassi
Rebecca Sassi
AZArina Alexandra Zamfir
Arina Alexandra Zamfir
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
Pain is a complex and burdensome symptom frequently experienced by oncological patients. Despite increased attention from healthcare providers and novel approaches, pain remains undertreated and prevalent in this patient population. Programs of patient education about pain (pain education, PE) have been proposed as a potential method to enhance pain management. However, the effectiveness of such programs and their impact on pain relief have shown variable results across studies. In this narrative review, we analyzed existing systematic reviews and meta-analyses on PE in oncological patients. A comprehensive literature search was conducted using PubMed, Scopus, and the Cochrane Library databases, following established guidelines. Studies meeting the selection criteria were selected and analyzed to evaluate the effectiveness of PE interventions. A total of nine publications, comprising six systematic reviews and three meta-analyses, were included. Across various clinical settings (inpatient and outpatient), the impact of pain education (PE) on pain intensity showed considerable variability: some reviews reported significant reductions, while others observed minimal or no effects. In contrast, PE consistently improved patients’ knowledge about pain and adherence to medication. However, the available evidence did not demonstrate significant improvements in quality of life. The observed heterogeneity in the results of pain relief outcomes could be attributed to the various types of pain analyzed and the diversity of clinical settings evaluated. Furthermore, differences in study designs, comprising the inclusion of non-randomized studies, contributed to the variability in findings. It remains unclear whether the effectiveness of PE is solely attributed to the educational content or if the attention provided to patients during the intervention partly explains the effect.

2 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
RHRenée Hovenier
Renée Hovenier
EHE.H. Huele
E.H. Huele
BBB.J.J. Bindels
B.J.J. Bindels
AOA. van Oss
A. van Oss
RKR.H. Kuijten
R.H. Kuijten
JVJ.M. van der Velden
J.M. van der Velden
This study aimed to evaluate the pain response following external beam radiotherapy (EBRT) in a large real-world cohort of patients with painful bone metastases. Patients receiving EBRT were enrolled in a prospective cohort. Pain scores and analgesic use were collected at baseline and until 12 weeks post-treatment. Pain response was defined as ≥ 2-point pain reduction (on 0-10 scale) without increased pain medication, or ≥ 25 % opioid reduction without pain increase. Logistic regression analyses were performed based on primary tumor type, baseline pain severity, baseline performance status, metastasis location, and treatment period. Survival was analyzed with the Kaplan-Meier method. Of 2363 patients enrolled between June 2013 and July 2024, 2067 (87%) were included for analyses. Seventy percent (n = 1442) of these analyzable patients experienced complete or partial pain response. The average pain score decreased from 5.9 at baseline to 3.7 at twelve weeks post-treatment. Patients with prostate or breast cancer and those with baseline pain scores ≥ 5 showed higher response rates (75%, 76%, and 73%, respectively). The pain response rate slightly increased from 67% (95%CI, 63-71) to 73% (95%CI, 69-77) (p = 0.037) over the last eleven years. Patients with pain response had longer median survival than non-responders (14 versus 6 months, p < 0.001). Approximately 70% of patients with painful bone metastases experience a partial or complete pain response after radiotherapy. Over the past decade, the pain response rate improved slightly from 67 to 73%.

5 December 2025 in The European Journal of Health Economics
Verified
Journal Article
Open access
PDF file
JGJulia Simoes Correa Galendi
Julia Simoes Correa Galendi
INIngrid Nijholt
Ingrid Nijholt
RHRenée Hovenier
Renée Hovenier
JSJorik Slotman
Jorik Slotman
EPErik Phernambucq
Erik Phernambucq
DMDirk Müller
Dirk Müller
Introduction: Non-randomized clinical trial has shown that Magnetic Resonance guided High-intensity focused ultrasound (MR-HIFU) leads to faster pain relief compared to the current standard of care External Beam Radiotherapy (EBRT). Objective: To evaluate the cost-utility of ’early MR-HIFU’ (with optional EBRT afterwards) or ‘delayed MR-HIFU’ (i.e., MR-HIFU after failed EBRT) versus EBRT (with optional re-irradiation with EBRT) from the societal perspective in the Netherlands Methods: A lifelong patient-level simulation model was developed. After a treatment with either MR-HIFU or EBRT, a patient could have: (i) complete pain relief, (ii) partial pain relief, (iii) persistent pain and (iv) death. We also accounted for the event of a pathological fracture. Model outputs were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER). The net monetary benefit was calculated considering the willingness-to-pay threshold of €80,000 per QALY gained, adjusted by the Dutch disease severity index. Deterministic and probabilistic sensitivity analyses were conducted. Results: The strategy ‘delayed MR-HIFU’ costs €706 more than EBRT, whilst ‘early MR-HIFU’ costs €1,875 more than EBRT.‘Early MR-HIFU’ adds 0,15 more QALYs than EBRT, resulting in an ICER of €12.755 per QALY and an incremental net monetary benefit of €8,631. At a threshold of 80,000€ per QALY there is a 77% probability that ‘early MR-HIFU’ is the most cost-effective option. Conclusion: Although there are still uncertainties relating to implementation of MR-HIFU in patient care, our modelling study shows that offering MR-HIFU as an early treatment would be the most cost-effective option in the Netherlands.

1 January 2025 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
RHRenée Hovenier
Renée Hovenier
DSDerk J. Slotman
Derk J. Slotman
CGChiara Gasperini
Chiara Gasperini
AZAlice Zamagni
Alice Zamagni
MHMira Huhtala
Mira Huhtala
HVHelena M. Verkooijen
Helena M. Verkooijen
Purpose: This prospective observational study aims to investigate which proportion of patients with bone metastases referred for External Beam Radiation Therapy (EBRT) would be able to undergo Magnetic Resonance‐guided High Intensity Focused Ultrasound (MR‐HIFU) as alternative to EBRT, and to examine reasons for ineligibility. Materials and Methods: Adult patients with nonspinal bone metastases referred to four radiotherapy departments were included. Local, multidisciplinary teams assessed which patients would be eligible for MR‐HIFU. The main reason(s) for ineligibility were categorized as patient‐related or lesion‐related. A random subsample of 30 ineligible patients were analyzed in detail to identify all reasons of ineligibility. Results: Overall, 57 of 741 (8%) nonspinal bone lesions were eligible for MR‐HIFU as alternative to EBRT. In total, 153 lesions (21%) in 130 patients were ineligible because of patient‐related factors, including curative treatment intent for oligo‐metastatic disease (10%), and poor performance status (8%). Of the remaining 588 bone metastases in 526 patients, 531 lesions (470 patients) were ineligible because of lesion‐related factors, including ‘lesion too extensive/advanced’ (29%), ‘(impending) pathological fracture’ (15%), ‘no moderate/severe pain from target lesion’ (11%). Proportion of ineligibility varied between centers from 70% to 96%, which was mainly attributable to differences in patient‐related factors. Within the random subsample of 30 ineligible patients, 27 patients had multiple reasons for ineligibility. Conclusion: A small proportion of patients, referred for EBRT of bone metastases, would be eligible to undergo MR‐HIFU as alternative palliation option. Taken together, patients presenting with small, localized lesions in nonspinal regions, primarily seeking pain relief without additional treatment goals are the most promising candidates for this therapy. These factors could be used to triage patients eligible for MR‐HIFU, thereby reducing unnecessary screening efforts, enhancing patient selection, and ultimately improve patient management strategies by optimizing the use of MR‐HIFU as a treatment option.

21 January 2025 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
RHRenée Hovenier
Renée Hovenier
CBClemens Bos
Clemens Bos
MBMartijn Boomsma
Martijn Boomsma
HGHolger Grüll
Holger Grüll
Alessio Giuseppe MorgantiAlessio Giuseppe Morganti
Alessio Giuseppe Morganti
HVHelena M. Verkooijen
Helena M. Verkooijen

23 March 2026 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
MKMaarten J. Kamphuis
Maarten J. Kamphuis
ISIrene C. van der Schaaf
Irene C. van der Schaaf
RGRoxanne Gal
Roxanne Gal
JVJoanne M. van der Velden
Joanne M. van der Velden
JBJ.P. Maarten Burbach
J.P. Maarten Burbach
HVHelena M. Verkooijen
Helena M. Verkooijen
To keep pace with rapid medical innovation, health care must be organized to enable systematic learning from every patient. The 'outpatient innovation clinic' was established to support this goal. This paper presents 12 years of experience with the outpatient innovation clinic, highlighting its approach, achievements, and challenges. Established in 2013 at the Division of Imaging and Oncology at University Medical Center Utrecht, the Netherlands, the outpatient innovation clinic provides an infrastructure to systematically enroll patients into prospective cohort studies. Patients are invited for a consultation with a clinical researcher, and informed consent is asked for the reuse of medical data, the collection of patient-reported outcome measures (PROMs), randomization into trials, biobanking, and recontact. The infrastructure serves as a platform for evidence-based innovation, following the idea, development, exploration, assessment, and long-term evaluation (IDEAL) framework. Between 2013 and 2025, eight prospective (international) multicenter observational cohorts of patients with primary tumors, metastatic cancer, or neurovascular malformations were established. Out of a total of 45,099 participants, 15,691 were enrolled at the innovation clinic. Of these, 13,172 (84%) provided additional informed consent for the collection of PROMs, and 11,833 (79%) for randomization into future trials within cohorts, either to serve as controls or to receive an invitation for participation. A large real-world data repository was generated and is used for technical product development and testing, hypothesis-generating studies, training and evaluation of (deep learning) algorithms, long-term PROMs analysis, and randomized treatment comparisons. Since 2014, five cohort-embedded trials have been completed, four are ongoing, and one is in preparation. The outpatient innovation clinic offers a successful infrastructure for (deep) learning from every patient and for evaluating medical innovations within the IDEAL framework, while safeguarding patients' autonomy over the reuse of their medical data.